Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMC-3G3 plus mitoxantrone + prednisone vs mitoxantrone + prednisone in metastatic castration-refractory prostate cancer
2009-018015-11Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of olaratumab in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Progression-free survival. Started May 2010; status: completed.
02
Drugs
olaratumab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2009-018015-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-018015-11.